In patients with Afib and CAD requiring anti platelet therapy, optimal anticoagulation is unknown. In this cohort, bleeding rates were 14/100 person years with triple therapy (warfarin + 2 anti platelets), ~7-11/100 person years for any dual therapies, and ~6-7/100 person years for any mono therapy. Compared to dual therapy, triple therapy was not associated with a reduction in the combined outcome of CV death, MI, stroke. Triple therapy increases bleeding, without apparent benefit, in patients with Afib and CAD (abstract)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment